Mogamulizumab
- Generic Name
- Mogamulizumab
- Brand Names
- Poteligeo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1159266-37-1
- Unique Ingredient Identifier
- YI437801BE
- Background
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect th...
- Indication
Mogamulizumab is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
- Associated Conditions
- Refractory Mycosis Fungoides and Sezary Syndrome, Relapsed Mycosis Fungoides/Sezary Syndrome
- Associated Therapies
- -
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT06698003
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06285370
- Locations
- 🇨🇳
Peking University First Hospital, Department of Dermatology and Venereology, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Department of Medical Oncology, Guangzhou, Guangdong, China
🇨🇳Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 20
- Registration Number
- NCT06235281
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Yale University
- Target Recruit Count
- 36
- Registration Number
- NCT05996185
- Locations
- 🇺🇸
Yale Cancer Center, Clinical Trials Office, New Haven, Connecticut, United States
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT05956041
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
- Conditions
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 10
- Registration Number
- NCT05414500
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04745234
- Locations
- 🇺🇸
New York Presbyterian Hospital, New York, New York, United States
🇺🇸University of California Irvine, Irvine, California, United States
🇪🇸Hospital del Mar, Barcelona, Spain
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
- Conditions
- Recurrent Sezary SyndromeMycosis FungoidesRefractory Mycosis Fungoides and Sezary SyndromeStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8Recurrent Mycosis Fungoides and Sezary SyndromeStage IV Mycosis Fungoides and Sezary Syndrome AJCC v8Recurrent Mycosis FungoidesRefractory Mycosis FungoidesRefractory Sezary Syndrome
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT04541017
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT04256018
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-04-05
- Target Recruit Count
- 43
- Registration Number
- NCT04128072
- Locations
- 🇩🇰
University Hospitals Copenhagen - Rigshospitalet, Copenhagen, Denmark
🇫🇷CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre, Bordeaux, France
🇪🇸Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.